Hepatic impairment: Starting dose

  • Because the exposure and toxicity of paclitaxel can be increased with hepatic impairment, administration of ABRAXANE in patients with hepatic impairment should be performed with caution
  • Patients with hepatic impairment may have a higher risk of toxicity, particularly from myelosuppression. Monitor these patients closely
  • Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
  • No dose adjustment is necessary for patients with mild hepatic impairment
  • Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance

Hepatic Impairment (Make a selection)

  • Mild
  • Moderate
  • Severe
  • Very Severe
MBC dose adjustments for hepatic impairment

Illustrative purposes only.

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >ULN to ?1.5 x ULN
MBC dose adjustments for hepatic impairment

Illustrative purposes only.

aA dose increase to 260 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles.

 

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >1.5 to ≤3 x ULN
MBC dose adjustments for hepatic impairment

Illustrative purposes only.

aA dose increase to 260 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for two cycles.

 

SGOT (AST) Levels <10 x ULN
AND
Bilirubin Levels >3 to ≤5 x ULN
Metastatic breast cancer dose adjustments for hepatic impairment

Illustrative purposes only.

SGOT (AST) Levels >10 x ULN
OR
Bilirubin Levels >5 x ULN
ULN=upper limit of normal.

Hepatic impairment: Starting dose

Hepatic Impairment (Make a selection)

  • Mild
  • Moderate
  • Severe
  • Very Severe

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.